Effective antitumor peptide vaccines can induce severe autoimmune pathology

Hussein Sultan, Jimena Trillo-Tinoco, Paulo Rodriguez, Esteban Celis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Immunotherapy has shown a tremendous success in treating cancer. Unfortunately, this success is frequently associated with severe autoimmune pathology. In this study, we used the transgenic RIP-gp mouse model to assess the antitumor therapeutic benefit of peptide vaccination while evaluating the possible associated autoimmune pathology. We report that palmitoylated gp33-41 peptide and poly-IC adjuvant vaccine (BiVax) generated ~ 5-10 % of antigen specific T cell responses in wild type and supposedly immune tolerant RIP-gp mice. Boosting with BiVax in combination with αCD40 antibody (TriVax) or BiVax in combination with IL-2/ αIL-2 antibody complexes (IL2Cx) significantly increased the immune responses (~30- 50%). Interestingly, although both boosts were equally effective in generating vast T cell responses, BiVax/IL2Cx showed better control of tumor growth than TriVax. However, this effect was associated with high incidence of diabetes in an antigen and CD8 dependent fashion. T cell responses generated by BiVax/IL2Cx, but not those generated by TriVax were highly resistant to PD-1/PD-L1 inhibitory signals. Nevertheless, PD-1 blockade enhanced the ability of TriVax to control tumor growth but increased the incidence of diabetes. Finally, we show that severe autoimmunity by BiVax/IL2Cx was prevented while preserving outstanding antitumor responses by utilizing a tumor antigen not expressed in the pancreas. Our data provides a clear evidence that peptide based vaccines can expand vast endogenous T cell responses which effectively control tumor growth but with high potential of autoimmune pathology.

Original languageEnglish (US)
Pages (from-to)70317-70331
Number of pages15
JournalOncotarget
Volume8
Issue number41
DOIs
StatePublished - Jan 1 2017

Fingerprint

Subunit Vaccines
Interleukin-2
Pathology
Antibodies
T-Lymphocytes
Neoplasms
Growth
CD8 Antigens
Peptides
Incidence
Neoplasm Antigens
Autoimmunity
Immunotherapy
Pancreas
Vaccination
Vaccines
Antigens

Keywords

  • Anti-CD40
  • Anti-tumor effect
  • Diabetes
  • IL-2 complex
  • Peptide vaccine

ASJC Scopus subject areas

  • Oncology

Cite this

Effective antitumor peptide vaccines can induce severe autoimmune pathology. / Sultan, Hussein; Trillo-Tinoco, Jimena; Rodriguez, Paulo; Celis, Esteban.

In: Oncotarget, Vol. 8, No. 41, 01.01.2017, p. 70317-70331.

Research output: Contribution to journalArticle

Sultan, Hussein ; Trillo-Tinoco, Jimena ; Rodriguez, Paulo ; Celis, Esteban. / Effective antitumor peptide vaccines can induce severe autoimmune pathology. In: Oncotarget. 2017 ; Vol. 8, No. 41. pp. 70317-70331.
@article{ac4f654df71e464e80b5a0842a4f29e6,
title = "Effective antitumor peptide vaccines can induce severe autoimmune pathology",
abstract = "Immunotherapy has shown a tremendous success in treating cancer. Unfortunately, this success is frequently associated with severe autoimmune pathology. In this study, we used the transgenic RIP-gp mouse model to assess the antitumor therapeutic benefit of peptide vaccination while evaluating the possible associated autoimmune pathology. We report that palmitoylated gp33-41 peptide and poly-IC adjuvant vaccine (BiVax) generated ~ 5-10 {\%} of antigen specific T cell responses in wild type and supposedly immune tolerant RIP-gp mice. Boosting with BiVax in combination with αCD40 antibody (TriVax) or BiVax in combination with IL-2/ αIL-2 antibody complexes (IL2Cx) significantly increased the immune responses (~30- 50{\%}). Interestingly, although both boosts were equally effective in generating vast T cell responses, BiVax/IL2Cx showed better control of tumor growth than TriVax. However, this effect was associated with high incidence of diabetes in an antigen and CD8 dependent fashion. T cell responses generated by BiVax/IL2Cx, but not those generated by TriVax were highly resistant to PD-1/PD-L1 inhibitory signals. Nevertheless, PD-1 blockade enhanced the ability of TriVax to control tumor growth but increased the incidence of diabetes. Finally, we show that severe autoimmunity by BiVax/IL2Cx was prevented while preserving outstanding antitumor responses by utilizing a tumor antigen not expressed in the pancreas. Our data provides a clear evidence that peptide based vaccines can expand vast endogenous T cell responses which effectively control tumor growth but with high potential of autoimmune pathology.",
keywords = "Anti-CD40, Anti-tumor effect, Diabetes, IL-2 complex, Peptide vaccine",
author = "Hussein Sultan and Jimena Trillo-Tinoco and Paulo Rodriguez and Esteban Celis",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19688",
language = "English (US)",
volume = "8",
pages = "70317--70331",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

TY - JOUR

T1 - Effective antitumor peptide vaccines can induce severe autoimmune pathology

AU - Sultan, Hussein

AU - Trillo-Tinoco, Jimena

AU - Rodriguez, Paulo

AU - Celis, Esteban

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Immunotherapy has shown a tremendous success in treating cancer. Unfortunately, this success is frequently associated with severe autoimmune pathology. In this study, we used the transgenic RIP-gp mouse model to assess the antitumor therapeutic benefit of peptide vaccination while evaluating the possible associated autoimmune pathology. We report that palmitoylated gp33-41 peptide and poly-IC adjuvant vaccine (BiVax) generated ~ 5-10 % of antigen specific T cell responses in wild type and supposedly immune tolerant RIP-gp mice. Boosting with BiVax in combination with αCD40 antibody (TriVax) or BiVax in combination with IL-2/ αIL-2 antibody complexes (IL2Cx) significantly increased the immune responses (~30- 50%). Interestingly, although both boosts were equally effective in generating vast T cell responses, BiVax/IL2Cx showed better control of tumor growth than TriVax. However, this effect was associated with high incidence of diabetes in an antigen and CD8 dependent fashion. T cell responses generated by BiVax/IL2Cx, but not those generated by TriVax were highly resistant to PD-1/PD-L1 inhibitory signals. Nevertheless, PD-1 blockade enhanced the ability of TriVax to control tumor growth but increased the incidence of diabetes. Finally, we show that severe autoimmunity by BiVax/IL2Cx was prevented while preserving outstanding antitumor responses by utilizing a tumor antigen not expressed in the pancreas. Our data provides a clear evidence that peptide based vaccines can expand vast endogenous T cell responses which effectively control tumor growth but with high potential of autoimmune pathology.

AB - Immunotherapy has shown a tremendous success in treating cancer. Unfortunately, this success is frequently associated with severe autoimmune pathology. In this study, we used the transgenic RIP-gp mouse model to assess the antitumor therapeutic benefit of peptide vaccination while evaluating the possible associated autoimmune pathology. We report that palmitoylated gp33-41 peptide and poly-IC adjuvant vaccine (BiVax) generated ~ 5-10 % of antigen specific T cell responses in wild type and supposedly immune tolerant RIP-gp mice. Boosting with BiVax in combination with αCD40 antibody (TriVax) or BiVax in combination with IL-2/ αIL-2 antibody complexes (IL2Cx) significantly increased the immune responses (~30- 50%). Interestingly, although both boosts were equally effective in generating vast T cell responses, BiVax/IL2Cx showed better control of tumor growth than TriVax. However, this effect was associated with high incidence of diabetes in an antigen and CD8 dependent fashion. T cell responses generated by BiVax/IL2Cx, but not those generated by TriVax were highly resistant to PD-1/PD-L1 inhibitory signals. Nevertheless, PD-1 blockade enhanced the ability of TriVax to control tumor growth but increased the incidence of diabetes. Finally, we show that severe autoimmunity by BiVax/IL2Cx was prevented while preserving outstanding antitumor responses by utilizing a tumor antigen not expressed in the pancreas. Our data provides a clear evidence that peptide based vaccines can expand vast endogenous T cell responses which effectively control tumor growth but with high potential of autoimmune pathology.

KW - Anti-CD40

KW - Anti-tumor effect

KW - Diabetes

KW - IL-2 complex

KW - Peptide vaccine

UR - http://www.scopus.com/inward/record.url?scp=85030254377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030254377&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19688

DO - 10.18632/oncotarget.19688

M3 - Article

AN - SCOPUS:85030254377

VL - 8

SP - 70317

EP - 70331

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -